GB1398347A - Prostaglandin intermediates - Google Patents
Prostaglandin intermediatesInfo
- Publication number
- GB1398347A GB1398347A GB4995074A GB4995074A GB1398347A GB 1398347 A GB1398347 A GB 1398347A GB 4995074 A GB4995074 A GB 4995074A GB 4995074 A GB4995074 A GB 4995074A GB 1398347 A GB1398347 A GB 1398347A
- Authority
- GB
- United Kingdom
- Prior art keywords
- formula
- hydroxy
- benzoyloxy
- lactones
- cyclopenta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000543 intermediate Substances 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- YVHAIVPPUIZFBA-UHFFFAOYSA-N cyclopentaneacetic acid Natural products OC(=O)CC1CCCC1 YVHAIVPPUIZFBA-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- LYHIYZUYZIHTCV-UHFFFAOYSA-N cyclopenta[b]pyran Chemical class C1=COC2=CC=CC2=C1 LYHIYZUYZIHTCV-UHFFFAOYSA-N 0.000 abstract 2
- -1 2-tetrahydropyranyl Chemical group 0.000 abstract 1
- XSDLSEOIVCVTQZ-UHFFFAOYSA-N 2h-cyclopenta[b]furan Chemical class C1=CC2=CCOC2=C1 XSDLSEOIVCVTQZ-UHFFFAOYSA-N 0.000 abstract 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 230000029936 alkylation Effects 0.000 abstract 1
- 238000005804 alkylation reaction Methods 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000001940 cyclopentanes Chemical class 0.000 abstract 1
- VONWDASPFIQPDY-UHFFFAOYSA-N dimethyl methylphosphonate Chemical compound COP(C)(=O)OC VONWDASPFIQPDY-UHFFFAOYSA-N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
- C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24799372A | 1972-04-27 | 1972-04-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB1398347A true GB1398347A (en) | 1975-06-18 |
Family
ID=22937208
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1542573A Expired GB1398346A (en) | 1972-04-27 | 1973-03-30 | Prostaglandins and the preparation thereof |
GB4995074A Expired GB1398347A (en) | 1972-04-27 | 1973-03-30 | Prostaglandin intermediates |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1542573A Expired GB1398346A (en) | 1972-04-27 | 1973-03-30 | Prostaglandins and the preparation thereof |
Country Status (7)
Country | Link |
---|---|
JP (1) | JPS5825668B2 (ja) |
BE (1) | BE798830A (ja) |
CH (1) | CH587811A5 (ja) |
FR (1) | FR2183036B1 (ja) |
GB (2) | GB1398346A (ja) |
NL (1) | NL7305434A (ja) |
ZA (1) | ZA732245B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5563397A (en) * | 1978-10-31 | 1980-05-13 | Mitsubishi Electric Corp | Manufacture of bolling heat transmission surface |
JPS61144268U (ja) * | 1985-02-27 | 1986-09-05 |
-
1973
- 1973-03-30 GB GB1542573A patent/GB1398346A/en not_active Expired
- 1973-03-30 GB GB4995074A patent/GB1398347A/en not_active Expired
- 1973-04-02 ZA ZA732245A patent/ZA732245B/xx unknown
- 1973-04-11 CH CH390276A patent/CH587811A5/xx not_active IP Right Cessation
- 1973-04-18 NL NL7305434A patent/NL7305434A/xx not_active Application Discontinuation
- 1973-04-25 JP JP48046326A patent/JPS5825668B2/ja not_active Expired
- 1973-04-26 FR FR7315128A patent/FR2183036B1/fr not_active Expired
- 1973-04-27 BE BE130508A patent/BE798830A/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CH587811A5 (ja) | 1977-05-13 |
FR2183036A1 (ja) | 1973-12-14 |
JPS4947350A (ja) | 1974-05-08 |
BE798830A (fr) | 1973-10-29 |
NL7305434A (ja) | 1973-10-30 |
ZA732245B (en) | 1974-03-27 |
FR2183036B1 (ja) | 1977-11-10 |
GB1398346A (en) | 1975-06-18 |
JPS5825668B2 (ja) | 1983-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4116988A (en) | 16-Phenoxy prostaglandin E1 analogs | |
GB1515415A (en) | Cyclopentane carbox aldehyde derivatives | |
GB1416410A (en) | Prostaglandin anologues | |
GB1398347A (en) | Prostaglandin intermediates | |
GB1372541A (en) | Cyclopentane derivatives | |
GB1424416A (en) | Prostaglandin intermediates and their preparation | |
CA1266668C (en) | OXAPROSTAGLANDIN ANALOG DERIVATIVES WITH 7-OXABICYCLOHEPTANE SUBSTITUTION | |
US4068083A (en) | 2,2-Difluoro-13,14-dihydro-PGE1 analogs | |
US4082783A (en) | 2A,2B-Dihomo-15-alkyl PGF1 α analogs | |
US3892795A (en) | 16-Methyl and 16,16 dimethyl PGA{HD 2 {B compounds | |
GB1345934A (en) | Cyclopentane derivatives | |
US3974193A (en) | 16-Fluoro prostaglandin B2 analogs | |
US3974191A (en) | 16-Fluoro prostaglandin F1 analogs | |
US3974190A (en) | 16-Fluoro prostaglandin A1 analogs | |
US3974192A (en) | 16-Fluoro prostaglandin B1 analogs | |
US3979435A (en) | 8β,12α-17-Phenyl-18,19,20-trinor-PGF2.sub.α compounds | |
US3979439A (en) | 8β,12α-17-Phenyl-18,19,20 trinor PGF2.sub.β compounds | |
US4212987A (en) | 2,2-Difluoro-PGE1 analogs | |
US3983165A (en) | 8β,12α,15β-17-Phenyl-18,19,20-trinor-PGF2.sub.αc | |
US3979438A (en) | 8β,12α-17-Phenyl-18,19,20-trinor-PGE2 compounds | |
US3989735A (en) | 4.5-Cis-didehydro-PGB1 analogs | |
US3975426A (en) | 8β, 11β, 12α-PGF2.sub.β -compounds | |
FR2201096A1 (en) | 5-Alkoxymethyl sulphamoyl-anthranilic acid derivs - diuretics and salure-tics from corresp 5-sulphamoyl-cpds with formaldehyde and alcohols | |
US3985787A (en) | 4,5-Cis-didehydro-PGA1 analogs | |
US4301294A (en) | 16-Phenoxy PGE2 compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PS | Patent sealed | ||
PCNP | Patent ceased through non-payment of renewal fee |